Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
10.1182/blood-2015-07-655860 89 MougiakakosD
The Low Dose is 1.6 mg (5 units), 5x per week
Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
Or maybe eight
This eliminates the financial anxiety of dose escalation and allows patients to adjust their medication safely based on clinical response rather than cost concerns
